Matthew Biegler
Stock Analyst at Oppenheimer
(1.95)
# 3,202
Out of 5,031 analysts
82
Total ratings
35.62%
Success rate
-5.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $9.84 | +184.55% | 3 | Oct 10, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $23 | $11.15 | +106.28% | 1 | Sep 4, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $22 | $9.36 | +135.04% | 7 | Sep 3, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.81 | +341.99% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $3.20 | +118.75% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.23 | +631.71% | 2 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $12.78 | -6.10% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $29.00 | +451.72% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $9.52 | +372.69% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $122.81 | -6.36% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $29.26 | +81.13% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $14.50 | +127.59% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.49 | +1,242.28% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.49 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $8.99 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.99 | +55.73% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.35 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.47 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.20 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.30 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.98 | - | 2 | Dec 22, 2022 |
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $9.84
Upside: +184.55%
BridgeBio Oncology Therapeutics
Sep 4, 2025
Initiates: Outperform
Price Target: $23
Current: $11.15
Upside: +106.28%
Olema Pharmaceuticals
Sep 3, 2025
Maintains: Outperform
Price Target: $22
Current: $9.36
Upside: +135.04%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.81
Upside: +341.99%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $3.20
Upside: +118.75%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.23
Upside: +631.71%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $12.78
Upside: -6.10%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $29.00
Upside: +451.72%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $9.52
Upside: +372.69%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $122.81
Upside: -6.36%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $29.26
Upside: +81.13%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $14.50
Upside: +127.59%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.49
Upside: +1,242.28%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $6.49
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $8.99
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $8.99
Upside: +55.73%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.35
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.47
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.20
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.30
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.98
Upside: -